Zyprexa

Worldwide, Other products fared better.

Sales of osteoporosis medication Forteo increased 59 per cent to $118 million, erectile dysfunction drug Cialis increased 38 per cent and four diabetes drugs climbed 11 per cent to a combined $750 million.

"Lilly is determined to be a leader in diabetes care," said Jim Ward, Lilly's executive director of investor relations.

Excluding certain charges in 2004 and 2005, as well as stock-option expensing in 2004, Lilly's earnings for the latest quarter would have risen to 80 cents per share, compared with 69 cents per share in the prior year.

Analysts polled by Thomson Financial expected earnings of 78 cents per share on $3.9 billion in sales.

For the full year, the company earned $1.98 billion, or $1.81 per share, versus $1.81 billion, or $1.66 a share, a year ago.

Sales rose to $14.65 billion from $13.86 billion.

Eli Lilly said it expects 2006 earnings of 73 cents to 75 cents per share for the first quarter and $3.10 to $3.20 per share for the year, with full-year sales up seven per cent to nine per cent.

Lilly shares fell eight cents to $57.09 in late trading on the New York Stock Exchange.

View more heart and stroke news PrintForwardBookmarkFeedbackTell us what you think!

...

Read more...